IL-33 is a chromatin-associated cytokine of the IL-1 family that has recently been linked to many diseases, including asthma, rheumatoid arthritis, atherosclerosis, and cardiovascular diseases. IL-33 signals through the IL-1 receptor-related protein ST2 and drives production of pro-inflammatory and T helper type 2-associated cytokines in mast cells, T helper type 2 lymphocytes, basophils, eosinophils, invariant natural killer T cells, and natural killer cells. It is currently believed that IL-33, like IL-1␤ and IL-18, requires processing by caspase-1 to a mature form (IL-33 112-270) for biological activity. Contrary to the current belief, we report here that full-length IL-33 1-270 is active and that processing by caspase-1 results in IL-33 inactivation, rather than activation. We show that full-length IL-33 1-270 binds and activates ST2, similarly to IL-33112-270, and that cleavage by caspase-1 does not occur at the site initially proposed (Ser 111), but rather after residue Asp178 between the fourth and fifth predicted ␤-strands of the IL-1-like domain. Surprisingly, the caspase-1 cleavage site (DGVD 178G) is similar to the consensus site of cleavage by caspase-3, and IL-33 is also a substrate for this apoptotic caspase. Interestingly, we found that full-length IL-33, which is constitutively expressed to high levels by endothelial cells in most normal human tissues, can be released in the extracellular space after endothelial cell damage or mechanical injury. We speculate that IL-33 may function, similarly to the prototypical alarmins HMGB1 and IL-1␣, as an endogenous danger signal to alert cells of the innate immune system of tissue damage during trauma or infection.
C
ytokines of the IL-1 family play a major role in a wide range of inflammatory, infectious, and autoimmune diseases (1, 2) . IL-33 [previously known as nuclear factor from high endothelial venule, or NF-HEV (3) ] is the most recent addition to the IL-1 family (4, 5) . Based on animal model studies and analyses of diseased tissues from patients, IL-33 has been proposed to represent a promising therapeutic target for several important diseases, including asthma and other allergic diseases (4), rheumatoid arthritis (5, 6) , atherosclerosis (7) , and cardiovascular diseases (8, 9) . IL-33 has been shown to signal through the IL-1 receptor-related protein ST2 (4) and to drive production of cytokines [both pro-inflammatory and T helper type 2 (Th2)-associated cytokines] and chemokines in mast cells, Th2 lymphocytes, basophils, eosinophils, invariant natural killer (NK) T cells, and NK cells (4, (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . IL-33 signaling has also been shown to require the IL-1 receptor (IL-1R) accessory protein, IL-1RAcP, indicating that IL-33 shares with IL-1 not only structural homology but also signaling pathways (11, 14) .
We initially discovered IL-33 as a nuclear factor abundantly expressed in endothelial cells of high endothelial venules in lymphoid organs (3, 5) , but we (20) and others (21) have recently found that IL-33 is also constitutively expressed to high levels in the nucleus of endothelial cells in other human tissues. These observations indicated that IL-33 is widely expressed along the vascular tree and that endothelial cells constitute a major cellular source of IL-33 in most human tissues (20, 21) . We also showed that nuclear IL-33 possesses transcriptional regulatory properties and associates with chromatin in vivo (5) . Recently, we found that IL-33 mimics Kaposi sarcoma herpesvirus for attachment to chromatin, and docks, through a short chromatin-binding peptide, into the acidic pocket formed by the histone H2A-H2B dimer at the surface of the nucleosome (22) . Together, our findings suggested IL-33 is a dual-function protein that may play important roles as both a cytokine and an intracellular nuclear factor (5, 22) . A similar duality of function has previously been shown for IL-1␣ and chromatin-associated cytokine HMGB1. IL-1␣, a cell-associated cytokine, exhibits potent proinflammatory cytokine activities mediated by the cell surface IL-1 receptors (1) but also functions intracellularly by translocating to the nucleus and regulating transcription (23) . HMGB1 regulates transcription and chromatin structure in the nucleus (24) but also functions extracellularly as a cytokine when secreted by activated macrophages during inflammation (25) or released by necrotic cells (26) . IL-1␣ has also been shown to be released by dying cells (1, (27) (28) (29) , and HMGB1 and IL-1␣ were thus defined as endogenous ''danger signals'' or ''alarmins'' that may alert the immune system after tissue damage during trauma or infection (30) .
It is currently believed that IL-33, like classical IL-1 family members IL-1␤ and IL-18, requires maturation by caspase-1 for optimal biological activity. This is based on the initial report by Schmitz et al., who indicated caspase-1 cleaves IL-33 after residue Ser 111 , resulting in the production of mature IL-33 112-270 (4) . Most of the studies that have been published to date used a recombinant IL-33 protein corresponding to this mature form. Here, we show that full-length IL-33 is biologically active, and that cleavage by caspase-1 does not occur at the site initially proposed but rather after residue Asp 178 within the IL-1-like domain. Consequently, caspase-1 processing results in inactivation of IL-33, rather than activation. We also demonstrate that full-length IL-33 can be released in the extracellular space after endothelial cell damage or injury. We discuss the possibility that IL-33 may function as an endogenous danger signal, like the prototypical alarmins IL-1␣ and HMGB1.
A).
We then tested the possibility that IL-33 may also be a substrate for other caspases. We found that incubation of in vitro translated full-length IL-33 protein with caspase-3, the prototypic apoptotic caspase, led to the production of a 20-22 kDa fragment very similar in size to the fragment observed after caspase-1 cleavage (Fig. 1B) . Like cleavage by caspase-1, cleavage of IL-33 by caspase-3 was specific, as it was not observed in the presence of the caspase-3 inhibitor Ac-DEVD-CHO. We concluded that full-length IL-33 1-270 protein can be cleaved by both caspase-1 and caspase-3 in vitro and that processing results in both cases in the generation of a 20-22 kDa cleavage product.
Schmitz et al. (4) suggested caspase-1 cleaves IL-33 1-270 after residue Ser 111 , resulting in the production of mature IL-33 112-270 , corresponding to the C-terminal IL-1-like cytokine domain. Unexpectedly, we discovered that the 20-22 kDa caspase-1 cleavage product does not correspond to the C-terminal IL-1-like domain, as initially proposed. Western blot analysis with antibodies specific for the N-and C-terminal domains of IL-33 [see supporting information (SI) Fig. S1 ] clearly revealed that antibodies directed against the first 15 amino-terminal residues of IL-33 (IL-33-Nter) recognize the 20-22 kDa caspase-1 cleavage product, whereas the Nessy-1 mAb, which is directed to the C-terminal IL-1-like domain (IL-33 179 -270 ), recognizes a smaller fragment of 12-13 kDa, migrating close to the gel front and found at very low levels compared with the full-length IL-33 protein (Fig. 1C) . We used an IL-33 protein tagged with myc-epitope at its carboxy-terminus in these experiments, and Western blot analysis with an anti-myc mAb detected the small 12-13 kDa fragment but not the 20-22 kDa form (Fig. 1C) , allowing us to independently confirm that the 20-22 kDa caspase-1 cleavage product corresponds to the N-terminal, rather than C-terminal, part of IL-33.
Caspase-1 Cleaves IL-33 After Residue Asp178 Within the IL-1-Like
Cytokine Domain. The size of the N-terminal fragment generated after caspase-1 processing indicated to us that cleavage must occur within the IL-1-like domain. Inspection of this region revealed the existence of a potential cleavage site (DGVD 178 G), similar to the consensus site of cleavage by caspase-3, and located between the fourth and fifth predicted ␤-strands of the IL-1-like domain ( Fig. 2A) . The possibility that caspase-1 may cleave IL-33 at this position was further supported by the observation that an in vitro translated fragment corresponding to IL-33 residues 1-178 co-migrated on SDS/PAGE with the 20-22 kDa caspase-1 cleavage product (Fig. 2B ). To provide definitive proof for caspase-1 cleavage of IL-33 after residue Asp 178 , a single mutation was introduced that replaced Asp 178 by an alanine. As shown in Fig. 2C , this mutation totally prevented the processing of full-length IL-33 by caspase-1. We concluded that caspase-1 cleaves IL-33 at the DGVD 178 G site. Mutation of Asp 178 to alanine also abrogated cleavage of IL-33 by caspase-3 ( Fig. 2D) , indicating that caspase-1 and caspase-3 cleave IL-33 at the same site within the IL-1-like domain. We then asked whether cleavage of IL-33 at this site occurs in cells undergoing apoptosis. WT IL-33 and the IL-33 D178A mutant were expressed in U2OS epithelial cells (Fig. S2) , and apoptosis was induced by treatment with the DNA-damaging agent doxorubicin. Western blot analysis revealed that WT IL-33, but not the IL-33 D178A mutant, is cleaved during doxorubicin-induced apoptosis and that cleavage can be prevented by pretreatment with the pan-caspase inhibitor Z-VAD-fmk (Fig. 2E ). We next looked at endogenous native IL-33. As endothelial cells constitute a major cellular source of IL-33 in human tissues (20, 21) , we selected human primary endothelial cells as a cellular system for these experiments. Western blot analysis revealed that endogenous IL-33 migrates as a 30-31 kDa band, the identity of which was validated after knockdown of IL-33 expression with specific siRNAs (Fig. 2F) . Treatment of the endothelial cells with the apoptosis-inducing agent staurosporine resulted in a complete maturation of endogenous IL-33 that was prevented by pretreatment with the pan-caspase inhibitor Z-VAD-fmk (Fig. 2G ). We concluded that native IL-33 is processed by endogenous caspases during apoptosis in primary human endothelial cells.
Full-Length IL-331-270 Binds and Activates the IL-33 Receptor ST2. As our data indicated that, unlike IL-1␤ and IL-18, cleavage of IL-33 by caspase-1 does not lead to the production of the mature IL-1-like domain, we then asked whether, similarly to the IL-1␣ precursor (1, 31) , full-length IL-33 1-270 may possess biological activity. We first tested the capacity of full-length IL-33 to bind to the ST2 receptor in pull-down experiments. We found that a human ST2-Fc fusion protein precipitates in vitro synthesized full-length IL-33 , similarly to the isolated IL-1-like domain IL-33 112-270 (Fig. 3A) . In contrast, the amino-terminal part of IL-33, IL-33 1-111 , did not bind to the ST2-Fc chimera protein. These results indicated that full-length IL-33 1-270 specifically binds to the ST2 receptor. Binding of full-length IL-33 to ST2 was also observed using endogenous native IL-33 obtained from endothelial cells extracts (Fig. 3B) , indicating the natively folded forms behave similarly to the in vitro generated forms regarding ST2 binding. We next investigated the capacity of full-length IL-33 1-270 to signal through ST2 by using a previously described NF-Bdependent reporter assay (4, 14) . HEK293T cells, transiently transfected with an expression vector for human ST2 together with an NFB-GFP reporter gene construct, were stimulated with full-length IL-33 , IL-33 , or IL-33 112-270 . As previously reported (4, 14) , a small population of cells expressed GFP in the absence of IL-33 stimulation. However, stimulation of cells with full-length IL-33 or the IL-1-like domain IL-33 112-270 , but not IL-33 , led to a significant increase in the number of GFP ϩ cells (Fig. 3C) . Quantification of the results by FACS analysis revealed that full-length IL-33 and the IL-1-like domain IL-33 112-270 possess a similar capacity to activate the NFB-GFP reporter gene construct (Fig. 3D) . We concluded that, similarly to IL-33 112-270 , full-length IL-33 1-270 is able to bind and activate the ST2 receptor.
The 2 Caspase-1 Cleavage Products, IL-331-178 and IL-33179-270, Do Not Activate ST2. As we found caspase-1 processing of IL-33 occurs within the IL-1-like domain, we predicted the 2 caspase-1 cleavage products, IL-33 and IL-33 179 -270 , would not exhibit biological activity. To confirm this prediction, we tested the capacity of IL-33 and IL-33 179 -270 to activate ST2 using the NFB-dependent GFP reporter assay. Immunofluorescence (Fig. 4A) and FACS (Fig. 4B ) analyses revealed that, whereas treatment of the cells with full-length IL-33 resulted in significant activation of ST2-dependent signaling, treatment with the 2 caspase-1 cleavage products did not activate the ST2-dependent NFB-GFP reporter gene. These results were confirmed using another bioassay, IL-33-dependent secretion of IL-6 by the mast cell line MC/9 (32). Full-length IL-33 significantly induced IL-6 secretion by MC/9 cells whereas the 2 caspase-1 cleavage products had no effect (Fig. 4C) . We con- cluded that, unlike full-length IL-33 1-270, the 2 caspase-1 cleavage products, IL-33 and IL-33 179 -270 , do not possess biological activity, indicating that caspase-1 processing inactivates IL-33.
IL-33 Is Released Extracellularly After Endothelial Cell Damage or
Injury. IL-33 and the alarmin HMGB1 are both chromatinassociated cytokines, and we then studied the possibility that full-length IL-33, similarly to HMGB1 (26) , may be released after cell damage or necrosis. We first tested the effect of mechanical injury on primary human endothelial cells that express high levels of endogenous IL-33 both in vivo (20, 21) and in culture (Fig. 5A) . Mechanical wounding of endothelial cells by cell scraping, a process that mimics the transient sublethal membrane disruptions that are observed in cells subjected to mechanical forces in vivo, has previously been shown to result in the release of growth factors such as basic FGF (33) . Interestingly, we found that full-length IL-33 was released from endothelial cells mechanically wounded by cell scraping (Fig. 5B) . HMGB1 was similarly released under these conditions. Scratching of endothelial monolayers by tracing lines with a surgical scalpel, a needle, or a pipette tip has been widely used as an in vitro model of wound healing. Using this model, we confirmed that IL-33, like HMGB1, is released into the supernatant after mechanical injury of endothelial cells. In contrast, IL-33 and HMGB1 were not released extracellularly in the absence of endothelial cell damage (Fig. 5B) . We then tested the effect of necrosis induced by several cycles of freezing and thawing (26) , and found IL-33 was released by necrotic cells and its levels in the supernatant increased with the number of freezing-thawing cycles (Fig. 5C) . Finally, full-length IL-33 and HMGB1 were also detected in the medium of endothelial cells treated with nonionic detergents Nonidet P-40 and Triton X-100, which provoke damage to the cell membrane (Fig. 5D) . Together, these data demonstrate that IL-33, like HMGB1, can be released in the extracellular space after endothelial cell damage or mechanical injury.
Discussion
In the present study, we demonstrate that IL-33 does not require maturation for binding and activation of the IL-33 receptor ST2, and that, contrary to the current belief, processing by caspase-1 results in IL-33 inactivation, rather than activation. Indeed, we unexpectedly discovered that cleavage of IL-33 by caspase-1 does not occur at the site initially proposed (Ser 111 ), but rather at a site located in the middle of the IL-1-like domain (DGVD 178 G). To the best of our knowledge, IL-33 is the first member of the IL-1 family shown to be inactivated after maturation by caspase-1. IL-33 thus differs from IL-1␤ and IL-18, which require maturation by caspase-1 for liberation of their mature biologically active forms (1, 2) ; from IL-1 family member IL-1F7, which requires caspase-1 processing for translocation to the nucleus (34); and from IL-1␣, which is not a substrate for caspase-1 but is cleaved by calpain to release a C-terminal 17 kDa form with biological activity (1) . IL-33 is therefore very unique in the IL-1 family, in terms of processing and biologically active domains. As our data convincingly demonstrate caspase-1 cleaves IL-33 at position D 178 but not at position S 111 , and no protease is known to cleave after S 111 , there is no evidence left for the existence of IL-33 112-270 either in vitro or in vivo.
The caspase-1 processing site within IL-33 is very similar to a consensus site for caspase-3, the pro-apoptotic caspase, and we found that IL-33 is cleaved at this site by caspase-1 and caspase-3 in vitro and by endogenous caspases in cells undergoing apoptosis. IL-33 is a potent stimulator of pro-inflammatory cytokine production by mast cells and other cells of the innate immune system (10, 11, 15, 18, 19) . Processing of IL-33 by caspases may therefore provide a mechanism to inactivate IL-33 proinflammatory cytokine activities during apoptosis, a process that does not trigger inflammation in vivo.
Similarly to IL-1␣ (1, 27-29), IL-33 may be released by damaged cells in vivo and function as an endogenous danger signal (35) , or alarmin (30) , to alert cells of the innate immune system of tissue injury. This possibility is supported by our data indicating that IL-33, which is constitutively expressed to high levels by endothelial cells in most normal human tissues (20, 21) , can be released in the extracellular space after endothelial cell damage or mechanical injury. Interestingly, IL-1␣ and the prototypical alarmin HMGB1 have also been shown to be released from damaged endothelial cells (28) , suggesting the endothelium may constitute a major source of danger signals in vivo. In addition to endothelium, we also detected abundant expression of IL-33 in the nucleus of epithelial cells of tissues in contact with the environment, including the skin and gastrointestinal tract, where pathogens, allergens, and other environmental agents are frequently encountered (20) . The constitutive expression of IL-33 in epithelial barriers of the human body thus supports the possibility that IL-33 may also play important roles as an epithelial alarmin. IL-33 is likely to be a very good alarm signal because it has the capacity to activate many actors of the innate immune system, including mast cells, basophils, eosinophils, NK cells, and invariant NK T cells (4, (10) (11) (12) (13) (15) (16) (17) (18) (19) . Among these, mast cells, which are strategically positioned close to vessel walls and epithelial surfaces exposed to the environment (36), the major sites of IL-33 expression in vivo (20) may play a major role in the response to the IL-33 danger signal. IL-33 is also able to activate Th2 cells (4, 14, 17, 18) and it may therefore play a role not only in the innate response, but also in the adaptive immune response, after tissue damage. Another property of IL-33 that qualifies it as a bona fide danger signal is the fact IL-33 signals through the TLR/IL-1R/MyD88 signaling pathway (4, 13, 17) , like IL-1␣ (27) and the exogenous danger signals from microorganisms, the so-called pathogen-associated molecular patterns. IL-33 may therefore represents a novel member of the damage-associated molecular pattern family, which regroups both endogenous (ie, alarmins) and exogenous (ie, pathogen-associated molecular patterns) danger signals (30) .
In summary, the results presented here are important because they demonstrate that IL-33 does not require maturation for biological activity and that, contrary to the current view, processing by caspase-1 results in IL-33 inactivation, rather than activation. In addition, the data reveal that full-length IL-33 can be released after endothelial cell damage or injury, suggesting IL-33 may function as a novel endogenous danger signal. Future studies will aim at defining the precise functions of IL-33 in human health and disease, including its roles in the tissue response to trauma or infection.
Materials and Methods
Plasmid Constructions and Protein Production. IL-33 deletion mutants were amplified by PCR using the human IL-33/NF-HEV cDNA (NM033439) (3, 5) as a template. The PCR fragments thereby obtained were cloned into plasmid pcDNA3.1A/myc-his (Invitrogen). The IL-33 D178A mutant was generated by PCR and cloned into the same expression vector. IL-33 and IL-331-178 deletion mutant were also cloned into plasmid pcDNA3 (Invitrogen) for use in experiments presented in Figs. 2, 3B , and 5B. Human IL-1␤ (NM000576.2) was amplified by PCR and cloned into vector pcDNA3.1A/myc-his. All primer sequences are available upon request. Pro-IL1␤, full-length IL-331-270, IL-33 D178A, and IL-33 deletion mutants were synthesized in vitro in rabbit reticulocyte lysate using the TNT-T7 kit with (fluorescent protein) or without (unlabeled protein) the FluoroTect GreenLys labeling system according to the manufacturer's instructions (Promega).
In Vitro Caspase Cleavage Assays. In vitro translated fluorescent or unlabeled proteins (5 L lysate) were incubated with various amounts of recombinant caspase-1 (Sigma) or caspase-3 (Calbiochem) in 14 L assay buffer (Calbiochem) for 2 h at 37°C. The resulting cleavage products were analyzed by SDS/PAGE and fluorography (Typhoon 9400 fluoroimager; GE Healthcare) or Western blot. In some experiments, caspases 1 and 3 were preincubated for 20 min at 37°C with 100 M of their respective inhibitors, Ac-YVAD-CHO and Ac-DEVD-CHO (Calbiochem).
Western Blot and Pull-Down Assays. Proteins were fractionated by SDS/PAGE, electroblotted, and detected with mAbs to myc-epitope tag (9E10, 1:1,000; Sigma), IL-33 (Nessy-1, 1:1,000; Alexis Biochemicals; 305B, 1:1,000; Alexis Biochemicals), or PARP (1:2,000; BD PharMingen), or rabbit antiserum to IL-33-Nter (IL-33 1-15, 1:400) (3, 5), IL-33-Cter (AT-110, no. 210 -447, 1:1,000; Alexis Biochemicals), or HMGB1 (Ab18256, 1:200; Abcam), followed by HRPconjugated goat anti-mouse or anti-rabbit Ig (1:10,000; Promega), and finally an enhanced chemiluminescence kit (GE Healthcare). Pull-down assays with human ST2-Fc chimera protein (1 g; R&D Systems) were performed as previously described (4), using in vitro translated IL-33 proteins (25 L lysate) or endothelial cell freeze-thaw extracts (3.5 ϫ 10 6 cells) containing endogenous native IL-33.
Reporter Gene Assays and ELISA. HEK293T cells (1.5 ϫ 10 5 cells/well in 12-well plates) were transfected with 2 g pNF-B-hrGFP (Stratagene) reporter plasmid and 1 g of pEF-BOS-hST2 (provided by S. Tominaga, Tochigi, Japan), using a phosphate calcium precipitation method. One day after transfection, cells were stimulated for 16 h with in vitro translated full-length IL-33 or deletion mutants (12.5 L lysate/well). Cells were then analyzed for GFP expression by fluorescence microscopy (Eclipse TE300 microscope; Nikon) and flow cytometry (FACScan, Cellquest Software; Becton Dickinson). DuoSet IL-6 ELISA assays (R&D Systems) were performed as described (32) 
